创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels: Advantages of MHC Humanized Mouse Models

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-06 14:44
  • Views:

(Summary description)With the deepening of biomedical research, the role of animal models in disease research, drug screening and therapeutic development has become increasingly prominent. Among them, mouse models have become the most commonly used experimental animals because their biological characteristics are highly similar to those of humans. However, traditional mouse models have obvious limitations in the study of certain human-specific diseases, especially those related to the immune system. In this regard, InnoModels Biotechnology has introduced the MHC (Major Histocompatibility Complex) humanized mouse model, which brings a breakthrough in biomedical research

InnoModels: Advantages of MHC Humanized Mouse Models

(Summary description)With the deepening of biomedical research, the role of animal models in disease research, drug screening and therapeutic development has become increasingly prominent. Among them, mouse models have become the most commonly used experimental animals because their biological characteristics are highly similar to those of humans. However, traditional mouse models have obvious limitations in the study of certain human-specific diseases, especially those related to the immune system. In this regard, InnoModels Biotechnology has introduced the MHC (Major Histocompatibility Complex) humanized mouse model, which brings a breakthrough in biomedical research

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-06 14:44
  • Views:
Information

With the deepening of biomedical research, the role of animal models in disease research, drug screening and therapeutic development has become increasingly prominent. Among them, mouse models have become the most commonly used experimental animals because their biological characteristics are highly similar to those of humans. However, traditional mouse models have obvious limitations in the study of certain human-specific diseases, especially those related to the immune system. In this regard, InnoModels Biotechnology has introduced the MHC (Major Histocompatibility Complex) humanized mouse model, which brings a breakthrough in biomedical research.
The greatest advantage of the MHC humanized mouse model is the high degree of humanization of the immune system, as the MHC region is responsible for encoding the major histocompatibility antigens in mice, which is closely related to the ability of the immune system to recognize "self" and "not-self". Through gene editing technology, InnoModels has successfully replaced the MHC region in mice with the human MHC region, making the immune response of these mice more similar to that of humans.

 


This highly humanized immune system makes the MHC humanized mouse model more representative for disease research. For example, in the fields of autoimmune diseases, transplant rejection, and infectious diseases, researchers can use these mouse models to more accurately mimic the pathogenesis of human diseases, thus providing a deeper understanding of the disease mechanisms and supporting the development of new therapeutic approaches.
In addition, the application of MHC humanized mouse models in drug discovery and development is also very promising. Since the immune system of these mice is similar to that of humans, the responses and effects of drugs in humans can be better predicted during new drug screening and efficacy assessment, reducing uncertainties and risks in clinical trials.
In summary, the MHC humanized mouse model of InnoModels provides a more realistic and effective tool for biomedical research. Its appearance not only enhances our understanding of human diseases, but also opens new doors for drug development and innovation of therapeutic methods. With the continuous advancement of technology and the expansion of application fields, we have reason to believe that the MHC humanized mouse model will play an even more important role in future biomedical research.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司